RxDoctor Payments Data

Wendell Danforth, MD

Ophthalmology · Kapolei, HINPI 1821043803

Payments from drug & device makers

$419in general payments, 2019–2025

Across 14 payments — averaging $29.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$197
  • Genentech USA, Inc.$65
  • Sun Pharmaceutical Industries Inc.$50
  • Mallinckrodt Hospital Products Inc.$29
  • Biogen$26
  • Tarsus Pharmaceuticals, Inc.$25
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$419 in reported general payments places this provider in the 20th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii

Medicare billing

Part B allowed, 2024
$1,102,493
Medicare patients
1,297
Services billed
13,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept14$34,617
LumiganBimatoprost42$30,608
XiidraLifitegrast16$27,669
RestasisCyclosporine25$25,523
Latanoprost969$20,468
RocklatanNetarsudil Mesylat/Latanoprost19$13,980
Prednisolone Acetate283$13,620
Brimonidine Tartrate161$9,367
SimbrinzaBrinzolamide/Brimonidine Tart33$7,875
VyzultaLatanoprostene Bunod13$7,347
Travoprost28$6,712
RhopressaNetarsudil Mesylate11$6,031
Alphagan PBrimonidine Tartrate17$5,846
Dorzolamide-TimololDorzolamide/Timolol/Pf26$5,542
CombiganBrimonidine Tartrate/Timolol11$5,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$18$35,01729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 120 ophthalmology providers in Hawaii.

Other ophthalmology in Kapolei

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →